Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

BioNTech SE (BNTX)

128.2   -1.19 (-0.92%) 03-24 16:00
Open: 128.5 Pre. Close: 129.39
High: 129.39 Low: 127.23
Volume: 617,104 Market Cap: 31,112(M)

Technical analysis

as of: 2023-03-24 4:24:30 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 158.03     One year: 165.76
Support: Support1: 124.58    Support2: 103.65
Resistance: Resistance1: 135.3    Resistance2: 141.92
Pivot: 130.16
Moving Average: MA(5): 131.33     MA(20): 129.98
MA(100): 149.04     MA(250): 149.92
MACD: MACD(12,26): -2.1     Signal(9): -2.7
Stochastic oscillator: %K(14,3): 47.3     %D(3): 66.1
RSI: RSI(14): 39.3
52-week: High: 188.98  Low: 117.08
Average Vol(K): 3-Month: 671 (K)  10-Days: 576 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BNTX ] has closed above bottom band by 24.2%. Bollinger Bands are 66.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 129.52 - 130.23 130.23 - 130.82
Low: 125.5 - 126.39 126.39 - 127.13
Close: 126.85 - 128.22 128.22 - 129.35

Company Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Headline News

Mon, 27 Mar 2023
Research Analysts Issue Forecasts for BioNTech SE's FY2022 ... - MarketBeat

Tue, 21 Mar 2023
BioNTech SE (NASDAQ:BNTX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Simply Wall St

Tue, 21 Mar 2023
Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in ... - Nasdaq

Mon, 20 Mar 2023
BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains ... - Nasdaq

Mon, 20 Mar 2023
BioNTech licenses solid tumor candidate from OncoC4 (NASDAQ ... - Seeking Alpha

Wed, 15 Mar 2023
FDA Approves Pfizer/BioNTech's Bivalent COVID-19 Vaccine For Youngest Kids - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 243 (M)
Shares Float 90 (M)
% Held by Insiders 64 (%)
% Held by Institutions 18.1 (%)
Shares Short 1,960 (K)
Shares Short P.Month 1,940 (K)

Stock Financials

EPS 41.95
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 76.44
Profit Margin (%) 55.5
Operating Margin (%) 68
Return on Assets (ttm) 42.8
Return on Equity (ttm) 76.2
Qtrly Rev. Growth -43.1
Gross Profit (p.s.) 66.21
Sales Per Share 76.47
EBITDA (p.s.) 52.45
Qtrly Earnings Growth -43.5
Operating Cash Flow 12,550 (M)
Levered Free Cash Flow 10,200 (M)

Stock Valuations

PE Ratio 3.05
PEG Ratio -0.1
Price to Book value 1.67
Price to Sales 1.67
Price to Cash Flow 2.47

Stock Dividends

Dividend 2.1
Forward Dividend 0
Dividend Yield 1.6%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.